ReviewCancer diagnosis & prognosis
Prognostic Significance of Platelet-to-Lymphocyte Ratio in Patients With Triple-negative Breast Cancer: Systematic Review and Meta-Analysis.
Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2026Article
- Low prognostic nutritional index score is associated with lymph node metastasis in patients with breast cancer, whereas hemoglobin-albumin-lymphocyte-platelet score is not.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: The platelet-to-lymphocyte ratio (PLR), a systemic inflammatory biomarker, has been linked to treatment response in breast cancer (BC). However, its prognostic value in triple-negative breast cancer (TNBC) remains unclear. This meta-analysis evaluated the association between PLR and survival outcomes in patients with TNBC. Materials and Methods: This study was registered on PROSPERO in January 2024 under protocol number CRD42024506786. Databases searched were PubMed, Embase and Cochrane Library in December 2024. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the association between PLR and overall (OS), progression-free (PFS), and disease-free (DFS) survival. Heterogeneity was assessed using I Results: Six studies with 819 patients with TNBC were included. PLR cut-off values were reported in five studies, determined either from previous research or receiver operating characteristic curves. A high PLR was not significantly associated with OS (HR=1.35, 95% CI=0.99-1.84; Conclusion: While PLR was not significantly associated with OS or PFS, it correlated with DFS in TNBC: These findings suggest that PLR may have prognostic value, but further large-scale studies are needed to establish its clinical utility and optimal cut-off values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.